Our findings are closest to those reported by Schmandt et al (2003) and Singer et al (2003), who also used the KIT CD117 polyclonal antibody (Dako), which is accepted for clinical use while assessing the KIT expression in GIST (Fletcher et al, 2002). Here, KIT is linked to gastrointestinal stromal tumor.